Product Reports Resources Pricing Login Book a demo

MyoKardia

Biotech & Life Sciences · San Francisco, United States · Founded 2012 · IPO 2015

Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases

Valuation $13B
Revenue $26M
Power Law Decacorn$10B+ valuation tier Colt$25–100M revenue
Knowledge graph
News Kardigan prices $400M IPO, extending biotech's hot streak Jun 19, 2026

Talent graph

MyoKardia's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 8 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on MyoKardia's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Cowen Group
Casdin Capital
Sanofi
BridgeBio
Cormorant Asset Management
Third Rock Ventures
Series B+ 4 investors entered at this stage
University of Colorado Boulder
Stanford University
Harvard University
Harvard Medical School

MyoKardia mafia

Startups founded by MyoKardia alumni

Former MyoKardia employees who went on to start their own companies. Sorted by Dealroom signal score.

KardiganEst. 2023
Jay EdelbergUnited States
Signal score94
BridgeBioEst. 2014
Neil KumarUnited States
Signal score93
AlumisEst. 2021
June LeeUnited States
Signal score91
HealthExEst. 2022
Priyanka Agarwal, MD, MBAUnited States
Signal score90
Maze TherapeuticsEst. 2018
Eric GreenUnited States
Signal score81
WithMe HealthEst. 2018
Ash DamleUnited States
Signal score79
Global Blood TherapeuticsEst. 2012
CHCharles HomcyUnited States
Signal score64
KainomyxEst. 2019
Suman NagUnited States
Signal score55

Book a demo to explore the full alumni network →

Global footprint

Where MyoKardia has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Patent intelligence

$44M patent portfolio · 31 active families

Estimated portfolio value
$44M
0.33% of market cap · 163.6× smaller than top peer Janssen Vaccines ($7.1B)
31 active patent families
Where MyoKardia innovates CardiomyopathyDiastolic functionHeart disease disorderHypertrophic cardiomyopathyLeft Ventricles

Where MyoKardia concentrates vs peers

Each axis is a top-10 topic across MyoKardia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about MyoKardia

An AI-synthesized read of the highest-engagement posts about MyoKardia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MyoKardia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles